“The company has decided not to proceed with a previously planned investment to build a biopharmaceutical facility in Ulverston as it no longer needs the additional capacity,” GSK said this week in a statement on reorganisation of its manufacturing.
It was back in 2012 that GSK announced plans for a new state-of-the-art biopharmaceutical manufacturing facility in Ulverston. [See our previous report here.]
The company is now carrying out a strategic review of its cephalosporins antibiotics business – medicines produce in Ulverston – and is considering selling the business.
The local council expressed its ‘shock and disappointment’ at the decision.
Councillor Graham Vincent said: “We have been in meetings and discussions with GSK in the last few weeks about unrelated matters and there was no suggestion that this announcement was on the horizon.”
GSK global affairs president Philip Thomson said: “We are continuing to invest in science and our core businesses in the UK and we continue to see the UK as an attractive place for the life sciences industry. We are working constructively with the government and others to develop an ambitious plan for the sector as part of the UK’s new industrial strategy.”
GSK said the decision was nothing to do with the UK’s decision to leave the European Union.